Literature DB >> 14703600

Sjögren's syndrome.

Habib Ur Rehman1.   

Abstract

Sjogren's syndrome (SS) describes xeropthalmia and xerostomia due to lymphocytic infiltrates of lacrimal and salivary glands. SS may occur alone (primary SS) or in association with several other autoimmune diseases (secondary SS). The clinical features involve a wide variety of organs, including skin, eyes, oral cavity and salivary glands, and systems, including nervous, musculoskeletal, genitourinary and vascular. Sicca symptoms can be found in a number of other disorders including rheumatoid arthritis, systemic lupus erythematosus, scleroderma, primary biliary cirrhosis, and other rheumatic disorders.

Entities:  

Mesh:

Year:  2003        PMID: 14703600     DOI: 10.3349/ymj.2003.44.6.947

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


  13 in total

1.  Effects of oral consumption of the green tea polyphenol EGCG in a murine model for human Sjogren's syndrome, an autoimmune disease.

Authors:  Kevin Gillespie; Isamu Kodani; Douglas P Dickinson; Kalu U E Ogbureke; Amy M Camba; Mengjie Wu; Stephen Looney; Tin-Chun Chu; Haiyan Qin; Frederick Bisch; Mohamed Sharawy; George S Schuster; Stephen D Hsu
Journal:  Life Sci       Date:  2008-09-06       Impact factor: 5.037

2.  An Unusual Initial Presentation of Sjögren's Syndrome: Severe Hypokalemic Paralysis Secondary to Distal Renal Tubular Acidosis.

Authors:  Erkan Sengul; Fatih Bunul; Ayten Yazici; Aysun Sengul; Sevim Dindar; Gökçen Selma Kilic Halhalli; Emine Binnetoglu
Journal:  Eurasian J Med       Date:  2013-10

3.  A Case of Primary Sjögren's Syndrome Presenting as Mass-Like Encephalitis, With Progression to Neuromyelitis Optica Spectrum Disorder.

Authors:  Hyun-Jung Lee; Sung Hae Chang; Eun Ha Kang; Yun Jong Lee; Yeong Wook Song; You-Jung Ha
Journal:  Arch Rheumatol       Date:  2017-04-04       Impact factor: 1.472

4.  Acute renal failure due to mesangial proliferative glomerulonephritis in a pregnant woman with primary Sjögren's syndrome.

Authors:  Fatma Ulku Adam; Dilek Torun; Filiz Bolat; Aysegul Zumrutdal; Siren Sezer; Fatma Nurhan Ozdemir
Journal:  Clin Rheumatol       Date:  2005-05-26       Impact factor: 3.650

5.  Clinical and laboratorial profile and histological features on minor salivary glands from patients under investigation for Sjögren's syndrome.

Authors:  Débora-Lima Pereira; Verônica-Silva Vilela; Teresa-Cristina-Ribeiro-Bartholomeu Dos Santos; Fábio-Ramôa Pires
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2014-05-01

6.  Randomized, Multicenter, Double-Blind Study of the Safety and Efficacy of 1%D-3-Hydroxybutyrate eye drops for Dry Eye Disease.

Authors:  Tetsuya Kawakita; Miki Uchino; Kazumi Fukagawa; Kenichi Yoshino; Seika Shimazaki; Ikuko Toda; Mari Tanaka; Hiroyuki Arai; Keiko Sakatani; Seiichiro Hata; Takashi Okano; Kazuo Tsubota
Journal:  Sci Rep       Date:  2016-02-11       Impact factor: 4.379

7.  Matrix metalloproteinases in recurrent corneal melting associated with primary Sjörgen's syndrome.

Authors:  Kristyna Brejchova; Petra Liskova; Enkela Hrdlickova; Martin Filipec; Katerina Jirsova
Journal:  Mol Vis       Date:  2009-11-14       Impact factor: 2.367

Review 8.  Renal involvement in autoimmune connective tissue diseases.

Authors:  Andreas Kronbichler; Gert Mayer
Journal:  BMC Med       Date:  2013-04-04       Impact factor: 8.775

9.  Effectiveness of low-dose doxycycline (LDD) on clinical symptoms of Sjögren's syndrome: a randomized, double-blind, placebo controlled cross-over study.

Authors:  Hubertus Seitsalo; Raija K Niemelä; Magdalena Marinescu-Gava; Tuija Vuotila; Leo Tjäderhane; Tuula Salo
Journal:  J Negat Results Biomed       Date:  2007-12-31

10.  Anti-cyclic citrullinated peptide antibodies in primary Sjögren syndrome may be associated with non-erosive synovitis.

Authors:  Fabiola Atzeni; Piercarlo Sarzi-Puttini; Nicola Lama; Eleonora Bonacci; Francesca Bobbio-Pallavicini; Carlomaurizio Montecucco; Roberto Caporali
Journal:  Arthritis Res Ther       Date:  2008-05-07       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.